- Conditions
- Atopic Dermatitis
- Interventions
- EDP1815, Placebo
- Drug
- Lead sponsor
- Evelo Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 3,785
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Dementia
- Interventions
- Allopregnanolone
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast
- Interventions
- QT Ultrasound scan
- Device
- Lead sponsor
- QT Ultrasound LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 755 participants
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Long Beach, California • Novato, California
- Conditions
- Central Nervous System Tumors
- Interventions
- Bevacizumab, Irinotecan, Temozolomide
- Drug
- Lead sponsor
- Johns Hopkins All Children's Hospital
- Other
- Eligibility
- 18 Months to 23 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Gout
- Interventions
- RDEA3170
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 4
- States / cities
- Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DA-1241, Placebo, Sitagliptin
- Drug
- Lead sponsor
- Dong-A ST Co., Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Miami, Florida • High Point, North Carolina + 1 more
- Conditions
- Skin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma, Skin Squamous Cell Carcinoma
- Interventions
- Biopsy Procedure, Natural Killer Cell Therapy, Surgical Procedure, Universal Donor Expanded TGF-beta-imprinted NK Cells
- Procedure · Biological
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Gout, Hyperuricemia
- Interventions
- Arhalofenate, Febuxostat, Colchicine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Intestinal Diseases, Colonic Diseases, Autoimmune Disease, Abdominal Pain
- Interventions
- KHK4083, Placebo
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
- Interventions
- Efgartigimod
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Interventions
- Gilteritinib, Vyxeos
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Prostate Cancer
- Interventions
- eRapa (encapsulated rapamycin)
- Drug
- Lead sponsor
- Rapamycin Holdings, Inc. dba Emtora Biosciences
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatorenal Syndrome, Acute Kidney Injury
- Interventions
- R2R01, Terlipressin
- Drug
- Lead sponsor
- River 2 Renal Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Nemvaleukin Alfa, Pembrolizumab
- Drug
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Miami, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 3 more
- Conditions
- AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Danvatirsen, Danvatirsen + Venetoclax
- Drug · Combination Product
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Houston, Texas
- Conditions
- Body Fat Disorder
- Interventions
- Zeltiq CoolSculpting System alone, Electromagnetic Muscle Stimulation alone, EMS followed by CoolSculping, CoolSculpting followed by EMS
- Device
- Lead sponsor
- Zeltiq Aesthetics
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Marina del Rey, California • Pleasanton, California • Sacramento, California + 1 more
- Conditions
- Atherosclerosis, Cardiovascular Disease
- Interventions
- MEDI6570, Placebo, Part B Placebo
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Anniston, Alabama • Jacksonville, Florida • Miami, Florida + 6 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Prostacyclin Receptor Agonist
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
- Interventions
- Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 25 more
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia
- Interventions
- NMS-03597812
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- Duarte, California • Aurora, Colorado • Newark, Delaware + 4 more
- Conditions
- Allergy
- Interventions
- Intradermal cat allergen challenge
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg, Miricorilant 10 mg
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
- Conditions
- Advanced Melanoma, Metastatic Melanoma
- Interventions
- Nivolumab, Ipilimumab
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more
- Conditions
- Cocaine Dependence
- Interventions
- dAd5GNE Vaccine, Placebo
- Biological
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 21 Years to 69 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York